2 terminated, 1 active not recruiting, 1 not yet recruiting. 2 Phase 1, 1 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Terminated 2 |
| Not applicable | 1 | Not yet recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow EGFR Exon 19 Deletion: new trials by email Literature Review of EGFR Exon 19 Deletion trials Research Report on EGFR Exon 19 Deletion
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO) Stereotactic Body Radiation Therapy SBRT - EGF-R Positive Non-Small Cell Lung Cancer, Non Small Cell Lung Cancer | Not applicable | Not yet recruiting | Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo | 35 | 2023-11-01 | 2023-08-21 |
| HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy Patritumab Deruxtecan, Platinum-based chemotherapy - Nonsquamous Non-small Cell Lung Cancer, EGFR L858R | Phase 3 | Active not recruiting | Daiichi Sankyo | 586 | 2022-07-08 | 2026-08-27 |
| (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC BLU-701, osimertinib, carboplatin - Lung Neoplasm, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 20 | 2022-01-13 | 2023-06-18 |
| (SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC BLU-945, osimertinib - Lung Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 1 | Terminated | Blueprint Medicines Corporation | 177 | 2021-06-29 | 2025-02-10 |
Carcinoma, Non-Small-Cell Lung (3) · Adenocarcinoma (2) · Bronchial Neoplasms (2) · Carcinoma (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Nerve Tissue (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2)
Bronchial Diseases (2) · Neoplasms, Glandular and Epithelial (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Lung Diseases (1) · Lung Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Respiratory Tract Diseases (1) · Respiratory Tract Neoplasms (1) · Thoracic Neoplasms (1)
osimertinib (2) · Carboplatin (1) · Pemetrexed (1) · Platinum Compounds (1) · Radiosurgery (1) · patritumab deruxtecan (1)
Blueprint Medicines Corporation (2) · Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo (1) · Daiichi Sankyo (1)
United States (3) · Canada (2) · France (2) · Japan (2) · Netherlands (2) · Singapore (2) · South Korea (2) · Spain (2) · Taiwan (2) · United Kingdom (2) · Australia (1) · Austria (1) · Belgium (1) · China (1) · Colombia (1)
Luis Rojas, MD (1)
2023 (1)